

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format no later than three weeks prior to your defence.

Basic information

Name: Anne Grosen

Email: anne.grosen@rm.dk

Phone: +45 7845 3813

Department of: Clinical Medicine

Main supervisor: Jens Kelsen

Title of dissertation: Effects of disease and medical therapy on sperm quality in men with inflammatory bowel disease

Date for defence: December 3, 2018 at (time of day): 14:00 Place: Aarhus Universitetshospital, Palle Juul-Jensens Boulevard 99, Indgang C, Plan 1, Auditorium C114-101, 8200 Aarhus N.

Press release (Danish)

Ny viden om sædkvalitet hos mænd med inflammatorisk tarmsygdom

Nyt ph.d.-projekt fra Health på Aarhus Universitet giver vigtig viden om, hvordan medicinsk behandling og sygdomsaktivitet påvirker sædkvaliteten hos mænd med kronisk tarmbetændelse. "Med projektets resultater kan vi berolige patienterne med, at hverken svær sygdomsaktivitet, behandling med immunhæmmende behandling eller nye biologiske lægemidler har markant effekt på sædkvaliteten," udtaler læge Anne Grosen, som forsvare sin afhandling ved en offentlig forelæsning på Aarhus Universitetshospital, mandag den 3. december 2018.

Kronisk tarmbetændelse rammer især yngre voksne. Viden om, hvordan sygdommen og medicinsk behandling påvirker forplantningsevnen er vigtig for at kunne rådgive patienterne rigtigt. Hidtil har forskning i forplantningsevnen fokuseret på kvindelige patienter. Derfor har forskere ved Lever-, Mave- og Tarmsygdomme, Aarhus Universitetshospital nu undersøgt, om medicinsk behandling med de udbredte lægemidler azathioprin og anti-TNF-alpha-hæmmere påvirker sædkvaliteten hos mænd med en af de to sygdomme Crohns sygdom og colitis ulcerosa. "Hos mænd i behandling med thiopuriner bevæger sædcellerne sig lidt mindre i forhold til raske mænd. Til gengæld var der ingen forskel i sædcellernes antal eller udseende, og medicinen påvirkede ikke sædcellernes DNA," udtaler Anne Grosen. Endvidere har forskerne vist, at behandling med TNF-hæmmere ikke nedsætter sædkvaliteten, og at selv svær indlæggelseskrævende opblussen i sygdommen kun påvirker sædcellernes bevægelighed, hvorimod DNA-integriteten er upåvirket.

"Resultaterne har stor betydning for vores rådgivning, da de fleste af vores patienter oplever tilbagevendende perioder med opblussen, der kræver immunhæmmende behandling og biologisk terapi. Samtidigt er mange af vores patienter yngre, som ønsker at stifte familie, ligesom andre unge," slutter Anne Grosen.

Forsvaret af ph.d.-projektet er offentligt og finder sted den 3. december 2018 kl. 14 på Aarhus Universitetshospital, indgang C, plan 1, auditorium C114-101, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N. Titlen på projektet er "Effects of disease and medical therapy on sperm quality in men with inflammatory bowel disease". Yderligere oplysninger: Ph.d.-studerende Anne Grosen, e-mail: anne.grosen@rm.dk, tlf. 7845 3813.

Bedømmelsesudvalg:

Sonia Friedman, overlæge, associate professor, Brigham and Women's Hospital, Division of Gastroenterology, Boston, USA

Torben Knudsen, ledende overlæge, klinisk lektor, dr.med., ph.d., Medicinsk Afdeling, Sydvestjysk Sygehus, Esbjerg

Ellen-Margrethe Hauge (formand), ledende overlæge, professor, PhD, Reumatologisk Afdeling, Aarhus Universitetshospital, Aarhus

Press release (English)

New insight on fertility in men with inflammatory bowel disease

A new PhD project from Aarhus University, Faculty of Health, provides new knowledge about the effect of medical treatment and disease activity on sperm quality in men with inflammatory bowel disease. The project was carried out by Anne Grosen, who defends her research results at a public lecture Monday, 3 December 2018.

The majority of patients with chronic inflammatory bowel disease are diagnosed as young adults. So far, research in reproduction has focused on female patients. Therefore, researchers from Department of Hepatology and Gastroenterology, Aarhus University Hospital have investigated the sperm quality in men with inflammatory bowel disease treated with either thiopurines, anti-TNF-alpha inhibitors, or admitted with severe active disease. "The results have provided reassurance for men with inflammatory bowel disease who plan pregnancy. Thiopurine treatment, anti-TNF- α therapy, and severe IBD flares have no alarming effects on sperm quality", Anne Grosen says.

"Consequently, men with IBD should be informed that pregnancy can be pursued without drug cessation. Further, patients should not fear adverse effects on fertility despite disease flares. This is relevant because the majority of patients will experience recurrent periods of disease flares that require immunomodulatory and biological therapy", Anne Grosen concludes.

The defence is public and takes place on 3 December 2018 at 14:00 at Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Entrance C, 1. floor, Auditorium C114-101, DK 8200 Aarhus N. The title of the project is "Effects of disease and medical therapy on sperm quality in men with inflammatory bowel disease." For more information, please contact PhD student Anne Grosen, email: anne.grosen@rm.dk, Phone +45 7845 3813.

Assessment committee:

Sonia Friedman, Associate professor, MD, Brigham and Women's Hospital, Division of Gastroenterology, Boston, USA

Torben Knudsen, Head of Department, Associate professor, MD, DSc, PhD, Department of Internal Medicine, Sydvestjysk Sygehus, Esbjerg, Denmark

Ellen-Margrethe Hauge, Head of Department, Professor, MD, PhD, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.